Applied Genetic Technologies Corp AGTC:NASDAQ

Last Price$1.98NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/06/21

Today's Change+0.04(2.06%)
Bid (Size)$1.83 (2)
Ask (Size)$2.50 (1)
Day Low / High$1.85 - 2.01
Volume25.00
 

View Biotechnology IndustryPeer Comparison as of 12/06/2021

 

Applied Genetic Technologies Corp ( NASDAQ )

Price: $1.98
Change: +0.04 (2.06%)
Volume: 25.00
4:00PM ET 12/06/2021
 
 

Avalon Globocare Corp ( NASDAQ )

Price: $0.94
Change: -0.009 (0.94%)
Volume: 53.4 K
4:00PM ET 12/06/2021
 
 

GlycoMimetics Inc ( NASDAQ )

Price: $1.55
Change: +0.02 (1.31%)
Volume: 584.7 K
4:00PM ET 12/06/2021
 
 

T2 Biosystems Inc ( NASDAQ )

Price: $0.55
Change: +0.02 (4.18%)
Volume: 784.00
4:00PM ET 12/06/2021
 
 

X4 Pharmaceuticals Inc ( NASDAQ )

Price: $3.46
Change: -0.10 (2.81%)
Volume: 422.4 K
4:00PM ET 12/06/2021
 

Read more news Recent News

Applied Genetic Technologies Names New Chief Medical Officer
5:06PM ET 10/14/2021 MT Newswires

Applied Genetic Technologies (AGTC) said Thursday that it has named Susan Schneider as chief medical officer. Prior to joining the company, Schneider...

Applied Genetic Technologies Fiscal Q4 Loss Narrows as Company Reports Revenue
4:35PM ET 9/23/2021 MT Newswires

Applied Genetic Technologies (AGTC) reported a fiscal Q4 net loss Thursday of $0.28 per diluted share, compared with a loss of $0.56 per share last year. ...

-- Earnings Flash (AGTC) APPLIED GENETIC TECHNOLOGIES CORPORATION Reports Q4 Revenue $500,000
4:07PM ET 9/23/2021 MT Newswires

...

Earnings Reaction History: Applied Genetic Technologies, 33.3% Follow-Through Indicator, 5.9% Sensitive
12:00PM ET 9/23/2021 MT Newswires

Expected Earnings Release: 09/23/2021, After-hours Avg. Extended-Hours Dollar Volume: $1,188,064 Applied Genetic Technologies (AGTC) is due to issue its...

Company Profile

Business DescriptionApplied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. View company web site for more details
Address14193 NW
Alachua, Florida 32615
Phone+1.386.462.2204
Number of Employees78
Recent SEC Filing12/06/20218-K
President, Chief Executive Officer & DirectorSusan B. Washer
Chief Financial OfficerJonathan I. Lieber
Chief Medical OfficerSusan Schneider
Chief Science OfficerAbraham Scaria

Company Highlights

Price Open$1.95
Previous Close$1.98
52 Week Range$1.85 - 9.67
Market Capitalization$84.9 M
Shares Outstanding42.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.69
Beta vs. S&P 500N/A
Revenue$24.2 M
Net Profit Margin-11,913.60%
Return on Equity-81.08%

Analyst Ratings as of 11/09/2021

Buy
9
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset